MTOR: good, bad, orugly?

Cardiovascular Research

Volumn 95, Issue 3, 2012, Pages 261-262

  Zhang, Yan ^a   Zhang, Ting ^a   Cao, Chun Mei ^a   Xiao, Rui Ping ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC ANTIBIOTIC; PROTEIN KINASE INHIBITOR;

APOPTOSIS; BIOACCUMULATION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CELL ENERGY; CELLULAR STRESS RESPONSE; COMPETITIVE INHIBITION; CONGESTIVE HEART FAILURE; DNA DAMAGE; DOWN REGULATION; EDITORIAL; ENERGY METABOLISM; ENZYME ACTIVATION; FATTY ACID OXIDATION; FIBROBLAST; GENOMIC INSTABILITY; GENOTOXICITY; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HIGH ENERGY PHOSPHATE; HIGH RISK POPULATION; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REINFORCEMENT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HEART DISEASE; MALE; NOTE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DNA DAMAGE; DOXORUBICIN; ENERGY METABOLISM; HEART DISEASES; MALE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84871674588     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs201     Document Type: Editorial

References (18)

1. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267-3285.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229. (Pubitemid 38720829)
3. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-352. (Pubitemid 46295436)
4. Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol 2006;329:657-668. (Pubitemid 44283720)
5. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006;41:389-405. (Pubitemid 44362995)
6. Nicolay K, Aue WP, Seelig J, van Echteld CJ, Ruigrok TJ, de Kruijff B. Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity. Biochim Biophys Acta 1987;929:5-13. (Pubitemid 17084440)
7. Seraydarian MW, Artaza L, Goodman MF. Adriamycin: effect on mammalian cardiac cells in culture. I. Cell population and energy metabolism. J Mol Cell Cardiol 1977;9: 375-382. (Pubitemid 8107105)
8. Maslov MY, Chacko VP, Hirsch GA, Akki A, Leppo MK, Steenbergen C et al. Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 2010;299:H332-H337.
9. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 2005;289:H37-H47. (Pubitemid 40934080)
10. Wang S, Song P, Zou MH. Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem 2012;287:8001-8012.
11. Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chaté V, Schnebelen C et al. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res 2012;95:290-299.
12. Li XN, Song J, Zhang L, LeMaire SA, Hou X, Zhang C et al. Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 2009;58:2246-2257.
13. Colombo SL, Moncada S. AMPKalpha1 regulates the antioxidant status of vascular endothelial cells. Biochem J 2009;421:163-169.
14. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008;9:702-712.
15. Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA et al. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 2007;130: 624-637. (Pubitemid 47277418)
16. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-293.
17. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 2011;52:497-500.
18. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 2011;89:309-319.